Estrogen Receptor Signaling in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Oct 14

PMID 37835383

Authors

Paulina Miziak

Marzena Baran

Ewa Blaszczak

Alicja Przybyszewska-Podstawka

Joanna Kalafut

Jolanta Smok-Kalwat

Magdalena Dmoszynska-Graniczka

Michal Kielbus

Andrzej Stepulak

Affiliations

Soon will be listed here.

Abstract

Estrogen receptor (ER) signaling is a critical regulator of cell proliferation, differentiation, and survival in breast cancer (BC) and other hormone-sensitive cancers. In this review, we explore the mechanism of ER-dependent downstream signaling in BC and the role of estrogens as growth factors necessary for cancer invasion and dissemination. The significance of the clinical implications of ER signaling in BC, including the potential of endocrine therapies that target estrogens' synthesis and ER-dependent signal transmission, such as aromatase inhibitors or selective estrogen receptor modulators, is discussed. As a consequence, the challenges associated with the resistance to these therapies resulting from acquired ER mutations and potential strategies to overcome them are the critical point for the new treatment strategies' development.

Citing Articles

Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.

Khanyile R, Chipiti T, Hull R, Dlamini Z Cancers (Basel). 2025; 17(5).

PMID: 40075655 PMC: 11899325. DOI: 10.3390/cancers17050808.

Pterostilbene as a potent ESR-1 in breast cancer therapy: insights from network pharmacology, molecular docking, dynamics simulations, ADMET, and in vitro analysis.

Marwah H, Dewangan H Mol Divers. 2025; .

PMID: 39992538 DOI: 10.1007/s11030-025-11144-3.

Novel Molecular Classification of Breast Cancer with PET Imaging.

Toan N Medicina (Kaunas). 2025; 60(12.

PMID: 39768978 PMC: 11678748. DOI: 10.3390/medicina60122099.

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.

Pasto B, Vida R, Dri A, Foffano L, Della Rossa S, Gerratana L Breast. 2024; 79:103859.

PMID: 39708442 PMC: 11872398. DOI: 10.1016/j.breast.2024.103859.

Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status.

Arumalla K, Haince J, Bux R, Huang G, Tappia P, Ramjiawan B Int J Mol Sci. 2024; 25(23).

PMID: 39684741 PMC: 11641454. DOI: 10.3390/ijms252313029.

References

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

Langdon S, Herrington C, Hollis R, Gourley C . Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers (Basel). 2020; 12(6). PMC: 7352420. DOI: 10.3390/cancers12061647. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Taylor A, Al-Azzawi F . Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000; 24(1):145-55. DOI: 10.1677/jme.0.0240145. View

Li L, Lee K, Han W, Choi J, Lee J, Kang G . Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet. 2010; 19(21):4273-7. DOI: 10.1093/hmg/ddq351. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Tharakan R, Lepont P, Singleton D, Kumar R, Khan S . Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol Cell Endocrinol. 2008; 295(1-2):70-8. DOI: 10.1016/j.mce.2008.07.018. View

Vadlamudi R, Rajhans R, Chakravarty D, Nair B, Nair S, Evans D . Regulation of aromatase induction by nuclear receptor coregulator PELP1. J Steroid Biochem Mol Biol. 2009; 118(4-5):211-8. PMC: 2826517. DOI: 10.1016/j.jsbmb.2009.09.009. View

10.

Brett J, Spring L, Bardia A, Wander S . ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021; 23(1):85. PMC: 8365900. DOI: 10.1186/s13058-021-01462-3. View

11.

Pedram A, Razandi M, Deschenes R, Levin E . DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell. 2011; 23(1):188-99. PMC: 3248897. DOI: 10.1091/mbc.E11-07-0638. View

12.

Umeh-Garcia M, OGeen H, Simion C, Hayden Gephart M, Segal D, Sweeney C . Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer. Br J Cancer. 2022; 127(3):436-448. PMC: 9346006. DOI: 10.1038/s41416-022-01812-8. View

13.

Yuen H, Chan Y, Grills C, McCrudden C, Gunasekharan V, Shi Z . Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. J Pathol. 2011; 224(1):78-89. DOI: 10.1002/path.2859. View

14.

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B . Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. J Hematol Oncol. 2015; 8:16. PMC: 4345016. DOI: 10.1186/s13045-015-0113-9. View

15.

Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F . ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001; 142(9):4120-30. PMC: 2040491. DOI: 10.1210/endo.142.9.8395. View

16.

Chiu H, Yeh Y, Wang Y, Huang W, Ho S, Lin P . Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Mol Cancer. 2016; 15(1):46. PMC: 4902929. DOI: 10.1186/s12943-016-0531-5. View

17.

Cao S, Lu C . Recent perspectives of breast cancer prognosis and predictive factors. Oncol Lett. 2016; 12(5):3674-3678. PMC: 5104147. DOI: 10.3892/ol.2016.5149. View

18.

Geiss-Friedlander R, Melchior F . Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007; 8(12):947-56. DOI: 10.1038/nrm2293. View

19.

Sareddy G, Vadlamudi R . PELP1: Structure, biological function and clinical significance. Gene. 2016; 585(1):128-134. PMC: 4838531. DOI: 10.1016/j.gene.2016.03.017. View

20.

Robertson J, Bondarenko I, Trishkina E, Dvorkin M, Panasci L, Manikhas A . Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016; 388(10063):2997-3005. DOI: 10.1016/S0140-6736(16)32389-3. View